119 related articles for article (PubMed ID: 18413795)
21. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.
Parry D; Guzi T; Shanahan F; Davis N; Prabhavalkar D; Wiswell D; Seghezzi W; Paruch K; Dwyer MP; Doll R; Nomeir A; Windsor W; Fischmann T; Wang Y; Oft M; Chen T; Kirschmeier P; Lees EM
Mol Cancer Ther; 2010 Aug; 9(8):2344-53. PubMed ID: 20663931
[TBL] [Abstract][Full Text] [Related]
22. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
[TBL] [Abstract][Full Text] [Related]
23. Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4.
Soni R; O'Reilly T; Furet P; Muller L; Stephan C; Zumstein-Mecker S; Fretz H; Fabbro D; Chaudhuri B
J Natl Cancer Inst; 2001 Mar; 93(6):436-46. PubMed ID: 11259469
[TBL] [Abstract][Full Text] [Related]
24. Off-target immune cell toxicity caused by AG-012986, a pan-CDK inhibitor, is associated with inhibition of p38 MAPK phosphorylation.
Lee DU; Jessen B
J Biochem Mol Toxicol; 2012 Mar; 26(3):101-8. PubMed ID: 22095879
[TBL] [Abstract][Full Text] [Related]
25. Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo.
Hirai H; Takahashi-Suziki I; Shimomura T; Fukasawa K; Machida T; Takaki T; Kobayashi M; Eguchi T; Oki H; Arai T; Ichikawa K; Hasako S; Kodera T; Kawanishi N; Nakatsuru Y; Kotani H; Iwasawa Y
Invest New Drugs; 2011 Aug; 29(4):534-43. PubMed ID: 20084424
[TBL] [Abstract][Full Text] [Related]
26. N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent.
Misra RN; Xiao HY; Kim KS; Lu S; Han WC; Barbosa SA; Hunt JT; Rawlins DB; Shan W; Ahmed SZ; Qian L; Chen BC; Zhao R; Bednarz MS; Kellar KA; Mulheron JG; Batorsky R; Roongta U; Kamath A; Marathe P; Ranadive SA; Sack JS; Tokarski JS; Pavletich NP; Lee FY; Webster KR; Kimball SD
J Med Chem; 2004 Mar; 47(7):1719-28. PubMed ID: 15027863
[TBL] [Abstract][Full Text] [Related]
27. GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models.
Hardwicke MA; Oleykowski CA; Plant R; Wang J; Liao Q; Moss K; Newlander K; Adams JL; Dhanak D; Yang J; Lai Z; Sutton D; Patrick D
Mol Cancer Ther; 2009 Jul; 8(7):1808-17. PubMed ID: 19567821
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic efficacy of the pan-cdk inhibitor PHA-793887 in vitro and in vivo in engraftment and high-burden leukemia models.
Alzani R; Pedrini O; Albanese C; Ceruti R; Casolaro A; Patton V; Colotta F; Rambaldi A; Introna M; Pesenti E; Ciomei M; Golay J
Exp Hematol; 2010 Apr; 38(4):259-269.e2. PubMed ID: 20167248
[TBL] [Abstract][Full Text] [Related]
29. A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer.
Lin SF; Lin JD; Hsueh C; Chou TC; Wong RJ
PLoS One; 2017; 12(2):e0172315. PubMed ID: 28207834
[TBL] [Abstract][Full Text] [Related]
30. Tangeretin induces cell-cycle G1 arrest through inhibiting cyclin-dependent kinases 2 and 4 activities as well as elevating Cdk inhibitors p21 and p27 in human colorectal carcinoma cells.
Pan MH; Chen WJ; Lin-Shiau SY; Ho CT; Lin JK
Carcinogenesis; 2002 Oct; 23(10):1677-84. PubMed ID: 12376477
[TBL] [Abstract][Full Text] [Related]
31. Impact of meriolins, a new class of cyclin-dependent kinase inhibitors, on malignant glioma proliferation and neo-angiogenesis.
Jarry M; Lecointre C; Malleval C; Desrues L; Schouft MT; Lejoncour V; Liger F; Lyvinec G; Joseph B; Loaëc N; Meijer L; Honnorat J; Gandolfo P; Castel H
Neuro Oncol; 2014 Nov; 16(11):1484-98. PubMed ID: 24891448
[TBL] [Abstract][Full Text] [Related]
32. SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling.
Barzegar M; Ma S; Zhang C; Chen X; Gu Y; Shang C; Jiang X; Yang J; Nathan CA; Yang S; Huang S
Br J Cancer; 2017 Oct; 117(8):1154-1163. PubMed ID: 28873083
[TBL] [Abstract][Full Text] [Related]
33. Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases.
Schonbrunn E; Betzi S; Alam R; Martin MP; Becker A; Han H; Francis R; Chakrasali R; Jakkaraj S; Kazi A; Sebti SM; Cubitt CL; Gebhard AW; Hazlehurst LA; Tash JS; Georg GI
J Med Chem; 2013 May; 56(10):3768-82. PubMed ID: 23600925
[TBL] [Abstract][Full Text] [Related]
34. Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells.
Xie S; Jiang H; Zhai XW; Wei F; Wang SD; Ding J; Chen Y
Acta Pharmacol Sin; 2016 Nov; 37(11):1481-1489. PubMed ID: 27569395
[TBL] [Abstract][Full Text] [Related]
35. The retinoic acid receptor antagonist, BMS453, inhibits normal breast cell growth by inducing active TGFbeta and causing cell cycle arrest.
Yang L; Ostrowski J; Reczek P; Brown P
Oncogene; 2001 Nov; 20(55):8025-35. PubMed ID: 11753686
[TBL] [Abstract][Full Text] [Related]
36. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
[TBL] [Abstract][Full Text] [Related]
37. Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function.
Foster JS; Henley DC; Bukovsky A; Seth P; Wimalasena J
Mol Cell Biol; 2001 Feb; 21(3):794-810. PubMed ID: 11154267
[TBL] [Abstract][Full Text] [Related]
38. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.
Fry DW; Harvey PJ; Keller PR; Elliott WL; Meade M; Trachet E; Albassam M; Zheng X; Leopold WR; Pryer NK; Toogood PL
Mol Cancer Ther; 2004 Nov; 3(11):1427-38. PubMed ID: 15542782
[TBL] [Abstract][Full Text] [Related]
39. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib.
Grösch S; Tegeder I; Niederberger E; Bräutigam L; Geisslinger G
FASEB J; 2001 Dec; 15(14):2742-4. PubMed ID: 11606477
[TBL] [Abstract][Full Text] [Related]
40. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
